Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT
Status:
Recruiting
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019,
which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) in the severe and critically
severe patients. Pulmonary edema is the key detrimental feature of ALI/ARDS. Autopsy of
patients died from COVID-19 reported that, pulmonary mucus exudation was severe, more obvious
than SARS infection. Pulmonary CT scanning and pathological findings also suggest that
pulmonary edema caused by inflammatory exudation is a distinguished feature of COVID-19.
However, specific pharmacotherapy is lacking.Vascular endothelial growth factor (VEGF) is
known as the most potent inducing factors to increase vascular permeability. Bevacizumab is
an anti VEGF recombinant humanized monoclonal antibody, which has been used in anti-tumor
treatment for 16 years. Evidence suggest that Bevacizumab is a promising drug for severe and
critical COVID-19 patients.
Phase:
N/A
Details
Lead Sponsor:
Qilu Hospital of Shandong University
Collaborators:
Ialy Moriggia Pelascini Gravedona Hospital S.p.A Jiangbei Union Hospital of Huazhong University of science and technology Renmin Hospital of Wuhan University Shandong Provincial Chest Hospital Wuhan University